Dimerix Limited · ASX:DXB
Dimerix — Gold Coast Investment Showcase (June 2017)
15 slides from Dimerix's conference presentation, Jun 22, 2017
Slide 1: A clinical phase company with a powerful drug discovery technology
For personal use only A clinical phase company with a powerful drug discovery technology Gold Coast Investment Showcase 22 June 2017 1
Slide 2: Disclaimer
Disclaimer For personal use only Some of the information in this presentation may refer to Dimerix Limited (“Dimerix” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all
Slide 3: Investment Highlights
Investment Highlights Dimerix Limited (ASX:DXB) For personal use only 1. Phase 2 clinical trial for a kind of chronic kidney disease (CKD) called FSGS 2. New clinical data to be announced in July 2017 – a key value inflection point 3. Relatively low cost and short timeframe of lead clinical program,
Slide 4: Corporate History
Corporate History For personal use only 2004 - 2014 2015 - 2017 2004 2004 - 2014 2015 2016 2017 - Positive FDA - Head of Drug - Dimerix - Pre-clinical and proof of - Listed on ASX meeting Development spun out of concept laboratory work appointed UWA - First patient - Interim Phase 2a - March 2014 CO
Slide 5: Experienced board and management
Experienced board and management For personal use only Dr James Williams – Executive Chairman David Franklyn – Director • Co-founder of Dimerix and iCeutica • Experienced Director of ASX-listed (acquired in 2011 and now with 3 FDA companies in a variety of sectors drug approvals) • Extensive experie
Slide 6: Corporate Overview
Corporate Overview For personal use only Corporate Snapshot Share price history ASX Code: DXB Share Price (20 Jun 17): $.009 0.02 Market cap: $16.5m Cash (31 Mar 2017): $2.8m Shares on issue*: 1,829.9m 0.01 Major Shareholders Mr Peter Meurs 17.33 0.00 Yodambao Pty Ltd 5.11 Mrs Wishney Sritharan Kris
Slide 7: Chronic kidney disease (CKD)
Chronic kidney disease (CKD) For personal use only • CKD is a growing global health problem affecting over 10% of the population • Damaged kidneys “leak” proteins into the urine. This is called proteinuria. • Proteinuria is the most common symptom of the disease and can indicate changes in kidney fu
Slide 8: Current Treatments
Current Treatments For personal use only • First line therapy are drugs to reduce blood pressure, which can reduce proteinuria but does not stop progression to kidney failure • In some types of kidney disease, patients are given a Will in remission cocktail of drugs including immunosuppressants and
Slide 9: Market opportunity
Market opportunity For personal use only • CKD is a global health problem with 26 million patients in the US alone • Growing in incidence due to large number of people living with obesity and diabetes • Medicare spending on end stage renal disease in 2014 was USD $32.8 billion – a massive drain on t
Slide 10: DMX-200 – lead product candidate
DMX-200 – lead product candidate For personal use only • DMX-200 is an ‘adjunct’ therapy – less complex development path • Patients continue taking their standard of care medication (irbesartan) and add a second drug to this (propagermanium) • Both drugs have been in use for many years, and their sa
Slide 11: DMX-200 Development & licensing timeline
DMX-200 Development & licensing timeline For personal use only Activity Q2 Q3 Q4 2018 2019 2020 2017 2017 2017 Phase 2a Manufacture of commercial tablet Human PK study - commercial tablet Phase 2b End of Phase 2 consultation with FDA Single pivotal Phase 3 Licensing opportunities Current development
Slide 12: Competitive landscape for FSGS
Competitive landscape for FSGS For personal use only • NASDAQ: RTRX • NASDAQ: CCXI • Market cap : ~US$ 674million • Market Cap: ~US$ 355 million • Phase 2 asset, sparsentan, for treating • Completed Phase 2 for CCX140 in FSGS – a dual angiotensin endothelin diabetic nephropathy – a CCR2 receptor blo
Slide 13: Dimerix Receptor-HIT platform
Dimerix Receptor-HIT platform For personal use only Receptor-HIT • Patented tool that enables understanding of receptor interactions • Particularly suited to GPCRs – most targeted receptor class for drug discovery • Can identify new uses for existing drugs and drive the discovery of new drugs and re
Slide 14: Investment Highlights
Investment Highlights Dimerix Limited (ASX:DXB) For personal use only 1. Phase 2 clinical trial for a kind of chronic kidney disease (CKD) called FSGS 2. New clinical data to be announced in July 2017 – a potential value inflection point 3. Relatively low cost and short timeframe of lead clinical pr
Slide 15: Contact
For personal use only Contact Kathy Harrison Chief Executive Officer +61 419 359 149 kathy.harrison@dimerix.com Dimerix Limited ACN 001 285 230 www.dimerix.com